Reports

Ideas That Generate Results

1. Analyst View

2. Research Methodology

3. Gene Therapy - An Introduction
     3.1 Classification of Gene Therapy Techniques
     3.2 Physical Methods of Gene Transfer
            3.2.1 Electroporation
            3.2.2 Hydrodynamic
            3.2.3 Microinjection
            3.2.4 Particle Bombardment
            3.2.5 Ultrasound-mediated Transfection
     3.3 Vectors for Gene Therapy
            3.3.1 Adenoviral Vectors
            3.3.2 Adeno-associated Virus Vectors
            3.3.3 Retroviral Vectors
            3.3.4 Lentiviral Vectors
            3.3.5 Plasmid DNA

4. Industry Trends and Drivers
     4.1 Industry Trends
            4.1.1 Gene Silencing: Gaining Momentum
            4.1.2 Advanced Therapies: Combining Gene Therapy and Stem Cell Technology
            4.1.3 Immunodeficiency Syndromes: The Focus of Gene Therapy
            4.1.4 Nanotechnology: Empowering Gene Therapy
            4.1.5 Gene Therapy: A New Hope to Treat Blindness
            4.1.6 Gene Therapy: Potential Cure for Cancer
     4.2 Market Drivers
            4.2.1 Failure of Conventional Therapies to Treat Cancers
            4.2.2 Entry of Gene Therapies in Developed Nations
            4.2.3 Rising Incidence of Chronic and Life Threatening Diseases
            4.2.4 Growing Interest of Venture Capital Firms

5. Market Restraints
     5.1 High Cost of Treatment
     5.2 Stringent Regulatory Laws & Safety Concerns
     5.3 Pitfalls in Current Technique

6. Gene Therapy Market Outlook
     6.1 Market Size and Growth
     6.2 Gene Therapy Clinical Trial Assessment
            6.2.1 By Geography
            6.2.2 By Indication
            6.2.3 By Gene Type
            6.2.4 By Vector
            6.2.5 By Clinical Trial Phase
     6.3 Gene Therapy Market by Application
            6.3.1 Oncology
                       6.3.1.1 Key Approaches
                       6.3.1.2  Recent Advancements
            6.3.2 Infectious Diseases
                       6.3.2.1 Key Approaches
                       6.3.2.2  Recent Advancements
            6.3.3 Genetic Disorders
                       6.3.3.1 Key Approaches
                       6.3.3.2  Recent Advancements
            6.3.4 Cardiovascular Disorders
                       6.3.4.1 Key Approaches
                       6.3.4.2  Recent Advancements
            6.3.5 Diabetes Mellitus
                       6.3.5.1 Key Approaches
                       6.3.5.2  Recent Advancements
            6.3.6 Neurological Disorders
                       6.3.6.1 Key Approaches
                       6.3.6.2  Recent Advancements

7. Gene Therapy Market - Regulatory Landscape
     7.1 US
            7.1.1 Regulatory Landscape
            7.1.2 Recent Advancements
     7.2 Europe
            7.2.1 Regulatory Landscape
            7.2.2 Recent Advancements
     7.3 Australia
            7.3.1 Regulatory Landscape
     7.4 Canada
            7.4.1 Regulatory Landscape
     7.5 Japan
            7.5.1 Regulatory Landscape
            7.5.2 Recent Advancement
     7.6 China
            7.6.1 Regulatory Landscape
     7.7 India
            7.7.1 Regulatory Landscape
            7.7.2 Recent Advancements

8. Advanced Gene Therapy Drugs
     8.1 Collategene
     8.2 Allovectin-7
     8.3 Generx
     8.4 Glybera

9. Mergers and Acquisitions
     9.1 Sangamo BioSciences to Acquire Gene Therapy Company Ceregene.
     9.2 Baxter to Acquire Chatham Therapeutics
     9.3 Bluebird Bio Acquired Privately Held Gene-Editing Company
     9.4 Miltenyi Acquired Gene Therapy Assets from Lentigen
     9.5 Dutch Player UniQure to Acquire InoCard GmbH for CHF Therapy.

10. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses, Key People)
     10.1 Spark Therapeutics, LLC
     10.2 ViroMed Co. Ltd. dba VM BioPharma
     10.3 Advantagene Inc
     10.4 Bluebird Bio
     10.5 Sanofi
     10.6 Genzyme - A Sanofi Company
     10.7 Kolon Life Science
     10.8 Vical Inc
     10.9 Oxford BioMedica
     10.10 Genethon